List view / Grid view
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began two new reviews and wrote guidance for healthcare professionals on the potential side effects of Strimvelis, Venclyxto and Zolgensma.
After 75 percent of obese patients treated with semaglutide lost at least 10 percent of their body weight, the drug has been submitted for regulatory approval in the UK, Europe and US.
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
Dr Lazar’s team identified that TZDs, while working for PPAR gamma, promoted the metabolism of glutamine, an amino acid...
A novel drug based on capsaicin caused long-term weight loss and improved metabolic health in mice eating a high-fat diet...
A compound that mimics a naturally occurring hormone that regulates appetite may help people who have obesity but not diabetes to lose weight...
Despite providing incentives to drug manufacturers to encourage the study of medications in children, few approved drugs include safe dosing information for obese children...
In a randomised clinical trial of women who were overweight or obese, mindfulness-based stress reduction (MBSR) increased mindfulness and decreased stress compared with health education.
Over the last decade, research has revealed more about the human gut microbiome—the environment within the gastrointestinal tract—where microbes, especially bacteria, reside.
2 December 2016 | By Niamh Louise Marriott, Digital Editor
O is for Obesity - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gelesis, a biotechnology company focused on developing products to safely induce weight loss and improve glycaemic control, have appointed David Pass, PhD as Chief Operating Officer...
3 June 2016 | By Victoria White, Digital Content Producer
Three-year data show early response to Novo Nordisk’s Saxenda (liraglutide 3 mg) resulted in improvements in weight loss and cardiometabolic risk factors...
